Pacific Biosciences Of California (PACB) Net Cash Flow Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.69 Bn | 175.40 Bn | 6.27 Bn |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn |
| 3 | Medtronic | 108.07 Bn | 98.85 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.93 Bn | 66.47 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.11 Bn | 44.44 Bn | 1.29 Bn |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.60 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.42 Bn | - |
| 9 | Koninklijke Philips | 24.05 Bn | 20.92 Bn | 2.07 Bn |
| 10 | Pacific Biosciences Of California | 418.97 Mn | 143.01 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.97% |
| Dec 31, 2025 | -11.91% |
| Sep 30, 2025 | -42.15% |
| Jun 30, 2025 | 30.92% |
| Mar 31, 2025 | -39.67% |
| Dec 31, 2024 | -45.59% |
| Sep 30, 2024 | -58.23% |
| Jun 30, 2024 | 36.20% |
| Mar 31, 2024 | -48.96% |
| Dec 31, 2023 | -60.66% |
| Sep 30, 2023 | 63.69% |
| Jun 30, 2023 | -127.12% |
| Mar 31, 2023 | 26.28% |
| Dec 31, 2022 | 33.19% |
| Sep 30, 2022 | 10.63% |
| Jun 30, 2022 | -78.38% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | 51.06% |
| Jun 30, 2021 | -152.59% |
| Mar 31, 2021 | 130.31% |